Skip to main content
PMC home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1996 Jul;27:S271–S278.

Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.

M Saunders 1, S Dische 1
PMCID: PMC2149999  PMID: 8763896

Abstract

The 40-year history of hypoxic cell sensitisation can be traced from hyperbaric oxygen to the present clinical studies with carbogen, nicotinamide and accelerated radiotherapy. A meta-analysis by Overgaard (1995) included 10703 cases entered into 83 randomised controlled trials and showed an overall improvement in local tumour control of 4.6% (P = 0.00001) and in survival of 2.8% (P = 0.005). Hyperbaric oxygen gave a 6.6% (P = 0.003) improvement in local control and hypoxic cell sensitisers 3.9% (P = 0.04). Despite this, the only hypoxic cell-sensitising method in routine clinical use is the giving of nimorazole in supraglottic and pharyngeal carcinomas. Acute, as well as chronic hypoxia has been recognised and nicotinamide, the amide derivative of B3 is believed to prevent the former. Thus ARCON (accelerated radiotherapy, carbogen and nicotinamide) has been introduced in the clinic in an effort to overcome tumour proliferation, chronic and acute hypoxia, respectively. The success of future randomised controlled trials would be improved greatly if methods were available to measure the concentration of hypoxic cells in tumours before treatment and thus select those where benefit may be gained. The use of ARCON recognises that tumour cell proliferation is an important cause of failure in addition to hypoxia. However, intrinsic radiosensitivity may also need to be taken into account in the future. Clinical trials aim to improve the therapeutic ratio and thus the study of morbidity is as important as local tumour control. International collaboration is essential if randomised controlled trials are to be carried out within reasonable periods of time.

Full text

PDF
S271

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADAMS G. E., DEWEY D. L. HYDRATED ELECTRONS AND RADIOBIOLOGICAL SENSITISATION. Biochem Biophys Res Commun. 1963 Aug 20;12:473–477. doi: 10.1016/0006-291x(63)90318-8. [DOI] [PubMed] [Google Scholar]
  2. Awwad H. K., Abd El Moneim H., Abd El Baki H., Omar S., El Merzabani M., Farag H. I. The topical use of misonidazole in bladder cancer. Prog Clin Biol Res. 1983;132D:305–316. [PubMed] [Google Scholar]
  3. Balmukhanov S. B., Beisebaev A. A., Aitkoolova Z. I., Mustaphin J. S., Philippenko V. I., Rismuhamedova R. S., Aisarova A. M., Abdrahmanov J. N. Intratumoral and parametrial infusion of metronidazole in the radiotherapy of uterine cervix cancer: preliminary report. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1061–1063. doi: 10.1016/0360-3016(89)90916-4. [DOI] [PubMed] [Google Scholar]
  4. Brown J. M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol. 1979 Aug;52(620):650–656. doi: 10.1259/0007-1285-52-620-650. [DOI] [PubMed] [Google Scholar]
  5. Bush R. S., Jenkin R. D., Allt W. E., Beale F. A., Bean H., Dembo A. J., Pringle J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl. 1978 Jun;3:302–306. [PMC free article] [PubMed] [Google Scholar]
  6. CHURCHILL-DAVIDSON I., SANGER C., THOMLINSON R. H. High-pressure oxygen and radiotherapy. Lancet. 1955 May 28;268(6874):1091–1095. doi: 10.1016/s0140-6736(55)90589-4. [DOI] [PubMed] [Google Scholar]
  7. Chassagne D., Sancho-Garnier H., Charreau I., Eschwege F., Malaise E. P. Progress report of a phase II and a phase III trial with etanidazole (SR-2508): a multicentre European study. Radiother Oncol. 1991;20 (Suppl 1):121–127. doi: 10.1016/0167-8140(91)90199-q. [DOI] [PubMed] [Google Scholar]
  8. Churchill-Davidson I., Foster C. A., Wiernik G., Collins C. D., Pizey N. C., Skeggs D. B., Purser P. R. The place of oxygen in radiotherapy. Br J Radiol. 1966 May;39(461):321–331. doi: 10.1259/0007-1285-39-461-321. [DOI] [PubMed] [Google Scholar]
  9. Dische S., Gray A. J., Zanelli G. D. Clinical testing of the radiosensitiser Ro-07-0582. II. Radiosensitisation of normal and hypoxic skin. Clin Radiol. 1976 Apr;27(2):159–166. doi: 10.1016/s0009-9260(76)80138-9. [DOI] [PubMed] [Google Scholar]
  10. Dische S. Hyperbaric oxygen: the Medical Research Council trials and their clinical significance. Br J Radiol. 1978 Nov;51(611):888–894. doi: 10.1259/0007-1285-51-611-888. [DOI] [PubMed] [Google Scholar]
  11. Dische S. Radiotherapy and anaemia--the clinical experience. Radiother Oncol. 1991;20 (Suppl 1):35–40. doi: 10.1016/0167-8140(91)90184-i. [DOI] [PubMed] [Google Scholar]
  12. Dische S., Rojas A., Rugg T., Hong A., Michael B. D. Carbogen breathing: a system for use in man. Br J Radiol. 1992 Jan;65(769):87–90. doi: 10.1259/0007-1285-65-769-87. [DOI] [PubMed] [Google Scholar]
  13. Dische S., Saunders M. I., Dunphy E. P., Bennett M. H., Des Rochers C., Stratford M. R., Minchinton A. I., Orchard R. A. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1109–1111. doi: 10.1016/0360-3016(86)90237-3. [DOI] [PubMed] [Google Scholar]
  14. Dische S. What have we learnt from hyperbaric oxygen? Radiother Oncol. 1991;20 (Suppl 1):71–74. doi: 10.1016/0167-8140(91)90191-i. [DOI] [PubMed] [Google Scholar]
  15. Evans R. G., Kimler B. F., Morantz R. A., Vats T. S., Gemer L. S., Liston V., Lowe N. A phase I/II study of the use of Fluosol as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumors. Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):415–420. doi: 10.1016/0360-3016(90)90551-t. [DOI] [PubMed] [Google Scholar]
  16. Haustermans K., van der Kogel A. J., Vanacker B., van der Schueren E. Influence of combined use of nicotinamide and carbogen on rat spinal cord radiation tolerance. Radiother Oncol. 1994 May;31(2):123–128. doi: 10.1016/0167-8140(94)90392-1. [DOI] [PubMed] [Google Scholar]
  17. Horsman M. R., Chaplin D. J., Brown J. M. Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res. 1989 Apr;118(1):139–150. [PubMed] [Google Scholar]
  18. Horsman M. R., Høyer M., Honess D. J., Dennis I. F., Overgaard J. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol. 1993 May;27(2):131–139. doi: 10.1016/0167-8140(93)90133-s. [DOI] [PubMed] [Google Scholar]
  19. Kjellen E., Joiner M. C., Collier J. M., Johns H., Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol. 1991 Oct;22(2):81–91. doi: 10.1016/0167-8140(91)90002-x. [DOI] [PubMed] [Google Scholar]
  20. Lavey R. S., Dempsey W. H. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1147–1152. doi: 10.1016/0360-3016(93)90536-5. [DOI] [PubMed] [Google Scholar]
  21. Lee D. J., Cosmatos D., Marcial V. A., Fu K. K., Rotman M., Cooper J. S., Ortiz H. G., Beitler J. J., Abrams R. A., Curran W. J. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):567–576. doi: 10.1016/0360-3016(95)00150-W. [DOI] [PubMed] [Google Scholar]
  22. Lustig R., Lowe N., Prosnitz L., Spaulding M., Cohen M., Stitt J., Brannon R. Fluosol and oxygen breathing as an adjuvant to radiation therapy in the treatment of locally advanced non-small cell carcinoma of the lung: results of a phase I/II study. Int J Radiat Oncol Biol Phys. 1990 Jul;19(1):97–102. doi: 10.1016/0360-3016(90)90140-f. [DOI] [PubMed] [Google Scholar]
  23. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509–518. [PubMed] [Google Scholar]
  24. Overgaard J., Hansen H. S., Andersen A. P., Hjelm-Hansen M., Jørgensen K., Sandberg E., Berthelsen A., Hammer R., Pedersen M. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1065–1068. doi: 10.1016/0360-3016(89)90917-6. [DOI] [PubMed] [Google Scholar]
  25. Rojas A. ARCON: accelerated radiotherapy with carbogen and nicotinamide. BJR Suppl. 1992;24:174–178. [PubMed] [Google Scholar]
  26. Rojas A., Carl U., Reghebi K. Effect of normobaric oxygen on tumor radiosensitivity: fractionated studies. Int J Radiat Oncol Biol Phys. 1990 Mar;18(3):547–553. doi: 10.1016/0360-3016(90)90059-s. [DOI] [PubMed] [Google Scholar]
  27. Rose C., Lustig R., McIntosh N., Teicher B. A clinical trial of Fluosol DA 20% in advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1325–1327. doi: 10.1016/0360-3016(86)90164-1. [DOI] [PubMed] [Google Scholar]
  28. Rubin P., Hanley J., Keys H. M., Marcial V., Brady L. Carbogen breathing during radiation therapy-the Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys. 1979 Nov-Dec;5(11-12):1963–1970. doi: 10.1016/0360-3016(79)90946-5. [DOI] [PubMed] [Google Scholar]
  29. Saunders M. E., Dische S., Anderson P., Flockhart I. R. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum. Br J Cancer Suppl. 1978 Jun;3:268–270. [PMC free article] [PubMed] [Google Scholar]
  30. Sotak C. H., Hees P. S., Huang H. N., Hung M. H., Krespan C. G., Raynolds S. A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy. Magn Reson Med. 1993 Feb;29(2):188–195. doi: 10.1002/mrm.1910290206. [DOI] [PubMed] [Google Scholar]
  31. Stratford M. R., Dennis M. F., Hoskin P. J., Saunders M. I., Hodgkiss R. J., Rojas A. Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. Acta Oncol. 1996;35(2):213–219. doi: 10.3109/02841869609098504. [DOI] [PubMed] [Google Scholar]
  32. Stratford M. R., Rojas A., Hall D. W., Dennis M. F., Dische S., Joiner M. C., Hodgkiss R. J. Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother Oncol. 1992 Sep;25(1):37–42. doi: 10.1016/0167-8140(92)90193-x. [DOI] [PubMed] [Google Scholar]
  33. Thomlinson R. H., Dische S., Gray A. J., Errington L. M. Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours. Clin Radiol. 1976 Apr;27(2):167–174. doi: 10.1016/s0009-9260(76)80139-0. [DOI] [PubMed] [Google Scholar]
  34. Urtasun R., Band P., Chapman J. D., Feldstein M. L., Mielke B., Fryer C. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 1976 Jun 17;294(25):1364–1367. doi: 10.1056/NEJM197606172942503. [DOI] [PubMed] [Google Scholar]
  35. Urtasun R., Feldstein M. L., Partington J., Tanasichuk H., Miller J. D., Russell D. B., Agboola O., Mielke B. Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial. Br J Cancer. 1982 Jul;46(1):101–108. doi: 10.1038/bjc.1982.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Zackrisson B., Franzén L., Henriksson R., Littbrand B., Stratford M., Dennis M., Rojas A. M., Denekamp J. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). Acta Oncol. 1994;33(4):377–381. doi: 10.3109/02841869409098432. [DOI] [PubMed] [Google Scholar]
  37. van der Maazen R. W., Thijssen H. O., Kaanders J. H., de Koster A., Keyser A., Prick M. J., Grotenhuis J. A., Wesseling P., van der Kogel A. J. Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother Oncol. 1995 May;35(2):118–122. doi: 10.1016/0167-8140(95)01534-n. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES